Current Research Studies
All of our studies are conducted at the Family Health Center, convieniently located at 26 Queen Street, Worcester, MA, 01610, which is across the street from Community Healthlink.
For more information about any of our current studies, please contact us:
The Residual Symptoms Study
The main goal of the study is to find out if the study drug, AVP-786, when taken in combination with a class of medications used for treating schizophrenia, improves residual symptoms of schizophrenia and impairments in cognitive function associated with schizophrenia. This study will also find out how safe the study drug is and how well the body accepts the study drug.
The Early Treatment Study 1
The goal of this study is to compare the standard treatment for psychosis with a treatment version of the medication aripiprazole that is taken only once each month. Study participants at this study location will receive the care your center usually provides. Those who qualify will receive study-related medical exams, and lab tests at no charge. People in this study will be compensated for their time. In order to participate in the study, individuals must be evaluated by a study doctor and meet certain criteria including, but not limited to:
- male or female aged 18-35
- have a clinical diagnosis of psychosis and up to 5 years of antipsychotic medication exposure
The Early Treatment Study 2
Are you between the ages of 18-35 and have a diagnosis of Schizophrenia or Schizophreniform disorder? If so, you may be eligible to participate in a research study conducted at Umass Medical School.
The purpose of this study is to help understand if the experimental drug paliperidone palmitate or oral antipsychotic medication is better at preventing a worsening of your symptoms of schizophrenia or schizophreniform disorder which could cause an unfavorable outcome.
The Smoking Study
The goal of this study is to find out whether use of a web-based decision support program leads to higher rates of people starting treatment to stop smoking than a computerized educational pamphlet. You will be compensated for your time.
The Nitroprusside Study
The goal of this 6-week research study is to assess the effectiveness of Sodium Nitroprusside, an FDA approved drug for management of hypertension, can improve symptoms of schizophrenia. We seek men and women ages 18-60 with a diagnosis of schizophrenia. Participants will be compensated for their time and travel, and all information will be kept private.
The Movement Study 1
Do involuntary body movements have a hold on you? We invite those who are experiencing involuntary movements in their face or other parts of their body – and suffer from schizophrenia or schizoaffective disorder, to see if they may qualify for the Kinect 3 Study. The purpose of this clinical research study is to evaluate the effectiveness, safety, and tolerability of an investigational oral medication for tardive dyskinesia. Each individual will be evaluated to determine his or her eligibility. Those who qualify will receive study medication, study-related medical exams, and lab tests at no charge.
The Movement Study 2
Do involuntary body movements have a hold on you? Are you diagnosed with bipolar disorder, mood disorder, schizoaffective disorder, or schizophrenia? People suffering from schizophrenia, schizoaffective disorder, bipolar disorder, and mood disorder may experience involuntary movements in their face or other parts of their body. We are conducting this research study to evaluate the safety and tolerability of an investigational drug for the treatment of tardive dyskinesia (TD). Each individual will be evaluated to determine his or her eligibility. Those who qualify will receive study medication, study-related medical exams, and lab tests at no charge.
The Movement Study 3
The purpose of this study is to provide subjects, who completed a previous Phase 3 investigational drug Valbenazine (NBI-98854) study, the opportunity to continue to receive treatment for Tardive Dyskinesia until the investigational drug Valbenazine (NBI-98854) is commercially available. In addition, this study will collect long-term safety and tolerability data of the investigational drug Valbenazine (NBI-98854), taken daily for up to 72 weeks (about 1 year and 6 months) in subjects with Tardive Dyskinesia. Subjects will be compensated for their participation in this research study.
The Memory Study
Have you been diagnosed with Schizophrenia or Schizoaffective disorder? Are you interested in helping us learn if a drug called Exenatide may improve your memory and thinking?
If so, you may be eligible to participate in a research study at UMass Medical School. Studies suggest that Exenatide (an FDA-approved drug) can reduce inflammation, which may protect the brain and improve memory and thinking in individuals with schizophrenia or schizoaffective disorder. Your participation in the study will last 24 weeks (6 months).
The Marijuana Study
People who have schizophrenia often abuse marijuana. We are studying whether FDA approved medication Clozapine can reduce marijuana use. The study lasts about 14 weeks and involves weekly meetings with the research staff, answering questions about substance use and current symptoms. Half the people in the study will get a medicine called “clozapine” and the other half will get a medicine called “risperidone”. People in the study will not know which type of pill they are getting.
We are looking for people who have been told they have schizophrenia, are willing to take medicine for schizophrenia, use marijuana regularly and are ages 18-55.